Pruritus Drug Pipeline Analysis Report 2025

Pruritus, commonly known as itching, is a condition characterized by an uncomfortable sensation that triggers the urge to scratch. It affects approximately 39.8% of the global population. This condition presents a significant unmet clinical need, as current treatment options, such as antihistamines and corticosteroids, often provide limited relief. With rising cases linked to chronic conditions like eczema, kidney disease, and liver disorders, the demand for more effective therapies is growing. Furthermore, increasing research on novel treatments, such as biologics and JAK inhibitors, alongside advancements in personalized medicine, is expected to drive the pruritus drug pipeline. The focus on developing targeted therapies offers hope for improved outcomes in the future.

Report Coverage

The Pruritus Drug Pipeline Insight Report by the publisher gives comprehensive insights into pruritus therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for pruritus. The pruritus report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The pruritus pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with pruritus treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to pruritus.

Pruritus Drug Pipeline Outlook

Pruritus, or itching, is a common symptom of numerous conditions, including dermatologic, systemic, and neurological disorders. It occurs when sensory nerve fibers in the skin are activated, leading to discomfort and scratching. The pruritus drug pipeline focuses on innovative treatments targeting the underlying causes, such as inflammation or immune dysfunction, to provide better symptom relief and improve quality of life.

Pruritus is commonly treated with antihistamines, corticosteroids, and topical emollients. In cases of chronic or severe pruritus, therapies such as JAK inhibitors, biologics, and phototherapy are gaining attention. These treatments aim to reduce inflammation and modulate immune responses to alleviate itching effectively.

Pruritus Epidemiology

A 2024 article on pruritus epidemiology highlighted a global prevalence of 39.8%, with the highest rates observed in individuals aged 65 and older. Women were more affected than men, showing a prevalence of 40.7% compared to 38.9%. Regional variations included the highest prevalence in Africa at 45.7%, followed by East Asia at 40.2% and Latin America at 36.5%. Europe recorded the lowest prevalence at 35.9%, while North America had a prevalence of 41.2%. BRICS countries exhibited a higher prevalence of 40.3%, compared to 38.7% in developed nations.

Pruritus Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of pruritus drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Biologics
• Monoclonal Antibodies
• Gene Therapies

By Route of Administration

• Oral
• Parenteral
• Others

Pruritus - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase III covers a major share of the total pruritus clinical trials.

Pruritus Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the pruritus pipeline analysis include small molecules, biologics, monoclonal antibodies, and gene therapies. The report provides a comparative analysis of the drug classes for each drug across various phases of clinical trials for pruritus.

Pruritus Clinical Trials Therapeutic Assessment - Competitive Dynamics

The pruritus drug report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in pruritus clinical trials:

• GlaxoSmithKline
• Regeneron Pharmaceuticals
• Xizang Haisco Pharmaceutical Co., Ltd.
• Sanofi
• Qilu Pharmaceutical (Hainan) Co., Ltd.
• Tharimmune Inc.
• Mirum Pharmaceuticals, Inc.
• Vifor Fresenius Medical Care Renal Pharma Ltd.
• Incyte Corporation
• Cara Therapeutics
• Bausch Health Companies Inc.

Pruritus Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for pruritus. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of pruritus drug candidates.

Drug: Maralixibat

The Phase 3 study sponsored by Mirum Pharmaceuticals, Inc. aims to evaluate the safety and efficacy of maralixibat in pediatric and adult participants with cholestatic liver disease and refractory pruritus. The study, expected to be completed by February 2027, will enroll 90 participants across multiple global sites, including North America, Europe, the Middle East, and South America.

Drug: Nalmefene

Tharimmune Inc. is sponsoring a Phase 2a study on the efficacy of TH104 in treating moderate to severe pruritus in primary biliary cholangitis (PBC) patients. The study will include 40 participants and is designed to evaluate TH104's effectiveness in managing pruritus. The study is expected to be completed by April 2026.

Drug: Ondansetron 8mg

The clinical trial sponsored by Wayne State University aims to examine the efficacy of ondansetron in preventing pruritus in patients undergoing cesarean sections under spinal anesthesia with morphine. The Phase 1 study will assess different timings of ondansetron administration to reduce pruritus and postoperative nausea or vomiting. The study is expected to be completed by December 2025, with 66 participants.

Reasons To Buy This Report

The Pruritus Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for pruritus. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within pruritus pipeline insights.

Key Questions Answered in the Pruritus - Pipeline Insight Report

• What is the current landscape of pruritus pipeline drugs?
• Which companies/institutions are developing pruritus emerging drugs?
• How many phase II drugs are currently present in pruritus pipeline drugs?
• Which company is leading the pruritus pipeline development activities?
• What is the current pruritus therapeutic assessment?
• What are the opportunities and challenges present in the pruritus drug pipeline landscape?
• What is the efficacy and safety profile of pruritus pipeline drugs?
• Which companies/institutions are involved in pruritus collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in pruritus?

This product will be delivered within 3-5 business days.